Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiovascular Devices In Brief

This article was originally published in The Gray Sheet

Executive Summary

ICD reimbursement: CMS has extended the review period for a national coverage decision on prophylactic ICD implantation until Nov. 27, in order to obtain more information from Guidant, who asked CMS to review the procedure. The request is based on the Guidant-sponsored MADIT-II trial and is supported by guidelines issued by ACC, AHA and NASPE (1"The Gray Sheet" Sept. 30, 2002, p. 9)...

You may also be interested in...



St. Jude Relying On ICD Boom To Weather Slowdown In Pacer Sales

St. Jude continues to benefit from the rapidly expanding ICD market, although pacemaker sales are constrained by competition from cardiac resynchronization therapy (CRT) devices for congestive heart failure

St. Jude Relying On ICD Boom To Weather Slowdown In Pacer Sales

St. Jude continues to benefit from the rapidly expanding ICD market, although pacemaker sales are constrained by competition from cardiac resynchronization therapy (CRT) devices for congestive heart failure

ICD Guidelines From ACC/AHA/NASPE Embrace MADIT-II Prophylactic Use

ICDs should be implanted in heart attack victims whose left-ventricular ejection fraction is 30% or less one month after the event and three months post-revascularization, according to new practice guidelines issued jointly by ACC, AHA and NASPE

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel